Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Sodium tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA
isolated as the main pharmacologically active natural compound from a traditional Chinese
herbal medicine,the dried root of Salvia miltiorrhiza Bunge known as Danshen. Danshen has
been known for the function of improving body functions such as activating blood circulation
and removing blood stasis according to the theory of traditional Chinese medicine. Danshen
and its various formula products including STS have been long-time widely used in oriental
countries, especially China to treat various inflammatory and cardiovascular diseases for its
pharmacological actions, including vasodilatation, anticoagulation, anti-inflammation, and
free radical scavenging,with negligible adverse effects observed.
The investigator's objective is to evaluate whether STS exhibits beneficial effects on
pulmonary hypertension. This is a randomized, controlled, multicentre clinical trial study.
90 patients with pulmonary hypertension will be enrolled in this study.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Collaborators:
Beijing Anzhen Hospital Beijing Chao Yang Hospital Dongguan People's Hospital Guangdong General Hospital Guangdong Provincial People's Hospital Jiangsu Carefree Pharmaceutical Co., Ltd. Qingdao University Second Affiliated Hospital of Xi'an Jiaotong University Sir Run Run Shaw Hospital The Affiliated Hospital of Qingdao University The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School The First Affiliated Hospital of Zhengzhou University